Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390701 | 0.73 | AXL (0.37) | CYP2A6 | |
| SCHEMBL7007696 | 0.69 | BACE1 (0.41) | TRPA1CA1CA2ITGB2ICAM1 | |
| SCHEMBL22127183 | 0.68 | NCF1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL31715595 | 0.67 | BACE1 (0.40) | TRPA1CA1CA2ITGB2ICAM1 | |
| SCHEMBL19925316 | 0.66 | MAOB (0.40) | MAOB | |
| SCHEMBL30540624 | 0.66 | MAOB (0.40) | MAOB | |
| SCHEMBL23625710 | 0.65 | APP (0.44) | TRPA1CA1CA2ITGB2ICAM1 | |
| SCHEMBL3096846 | 0.65 | MAOB (0.36) | TRPA1CA1CA2ITGB2ICAM1 | |
| SCHEMBL421423 | 0.65 | AHR (0.43) | TRPA1CA1CA2ITGB2ICAM1 | |
| SCHEMBL7016588 | 0.65 | USP2 (0.43) | TRPA1CA1CA2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| CN-102892767-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO (US) | 2013-01-23 | — | — | CN | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | TRPA1 4687/4885CA1 4243/4885CA2 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.